ESR1 and breast carcinoma: To determine its activity, the effect of the newly synthesized compound was tested on estrogen-receptor-positive (ER+) breast cancer, which is characterized by aromatase overexpression on MCF-7 cells, as well as on the breast-cancer-cell-line-resistant LTED.